The molecular oncology laboratory is part of the Molecular Diagnostics Section in charge of testing for molecular markers important in many neoplastic conditions. Our current testing menu includes:
- BCR::ABL1 quantitative, p210 major breakpoint
- BCR::ABL1 quantitative, p190 minor breakpoint
- PML::RARA, quantitative, bcr 1 (long) and bcr 3 (short) forms
- BRAF mutational analysis
- EGFR mutational analysis
- KRAS mutational analysis
- NRAS mutational analysis
- Immunoglobulin heavy chain gene rearrangement (B-cell clonality)
- T-cell receptor gamma gene rearrangement (T-cell clonality)
- FLT3 mutation analysis (ITD and TKD mutations)
- Next-Generation Sequencing (NGS) for myeloid neoplasms
- Next-Generation Sequencing (NGS) for solid tumors
All specimens submitted for analysis must be accompanied by a requisition form.
Samples may be submitted in several ways:
- Formalin-fixed paraffin embedded (FFPE) tissues, on either glass slides or block (with H&E slide and specified percent tumor).
- Peripheral blood/ bone marrow samples (should be collected in EDTA only).
- Body fluid samples (require a dedicated sample).
- Tubes that have been opened and samples for obtained for other tests will be considered on a case-by-case basis (at the director's discretion).
Normal turnaround time is estimated to be 3-5 days depending upon the day the sample is received and the test being performed.